IHC - CD57

IHC – CD57 Test

The IHC CD57 Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD57 protein expression in tissue samples. CD57 is a cell surface marker commonly expressed on natural killer (NK) cells, subsets of T-lymphocytes, neural tissue, and selected neuroendocrine cells, making it highly valuable in hematopathology and tumor classification.

This test plays an important role in identifying and classifying NK-cell neoplasms, T-cell lymphomas, neuroendocrine tumors, and selected neural tumors. It helps pathologists determine cellular origin and supports differential diagnosis when routine histopathology findings are inconclusive.

The IHC CD57 test is commonly used in evaluating:

• NK/T-cell lymphoma
• Peripheral T-cell lymphoma
• Neuroendocrine tumors
• Neural and peripheral nerve sheath tumors
• Differential diagnosis of hematologic and neural tumors

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy or surgical specimens using advanced antibody staining techniques. Expert pathologists examine stained tissue microscopically to assess CD57 protein expression and determine tumor lineage.

CD57 is often included as part of a broader immunophenotyping panel alongside markers such as CD3, CD56, CD2, CD45, chromogranin, synaptophysin, and S100, depending on the suspected diagnosis.

This test is especially useful when confirming NK-cell differentiation, neural origin, or neuroendocrine characteristics of a tumor.

Accurate CD57 expression analysis helps oncologists confirm diagnosis, assess prognosis, and guide personalized treatment planning.

Benefits of the Test

• Detects CD57 protein expression accurately
• Supports NK-cell and T-cell tumor diagnosis
• Helps classify neuroendocrine and neural tumors
• Assists differential diagnosis
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CD57 IHC Test when:

• NK/T-cell lymphoma is suspected
• Neural tumor classification is required
• Neuroendocrine differentiation needs confirmation
• Routine biopsy findings are inconclusive
• Differential diagnosis is necessary
• Advanced tumor classification is needed
• Treatment planning depends on exact diagnosis
• Expert pathology confirmation is required

This test improves diagnostic confidence for accurate cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant imaging and clinical records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CD57 IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected NK-cell or T-cell tumors
• Individuals requiring neural tumor classification
• Patients undergoing neuroendocrine tumor evaluation
• Individuals with unclear tissue diagnosis
• Oncology patients under specialist care
• Patients requiring advanced immunohistochemistry confirmation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert pathology specialists ensure highly accurate CD57 IHC reports for reliable diagnosis and personalized cancer treatment planning.